v3.26.1
Segment information
6 Months Ended
Jun. 30, 2026
Segment information  
Segment information

13.        Segment information

The Company views its operations and manages its business in one operating segment: life science. The Company expects to continue to incur significant expenses as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. The table below summarizes the significant expense categories for the life science segment regularly reviewed by the chief operating decision maker for the three and six months ended June 30, 2026 and 2025:

Three months ended June 30,

Six months ended June 30,

2026

2025

2026

2025

Total revenues

$

360,519

$

178,875

$

633,070

$

1,354,971

Less:

Cost of product, collaboration and license sales

10,933

8,093

30,611

15,800

Program spend

42,580

49,705

80,125

97,863

Employee costs

68,348

65,593

144,469

133,292

Manufacturing costs

6,232

19,519

15,317

34,470

Administrative costs

16,547

17,896

33,236

36,310

Occupancy costs

7,493

6,643

15,848

13,825

Other segment items (a)

124,890

76,275

232,777

221,698

Segment net income (loss)

$

83,496

$

(64,849)

$

80,687

$

801,713

Reconciliation of profit or loss

Adjustments and reconciling items

Consolidated net income (loss)

$

83,496

$

(64,849)

$

80,687

$

801,713

(a)Other segment items includes the following:

Three months ended June 30,

Six months ended June 30,

2026

2025

2026

2025

Interest income

$

(18,119)

$

(20,991)

$

(36,104)

$

(38,236)

Interest expense

66,600

51,349

133,615

102,686

Income tax expense (benefit)

14,049

(6,203)

14,396

57,063

Depreciation

4,009

3,573

7,815

7,031

Amortization

11,841

4,061

23,422

7,859

All other (b)

46,510

44,486

89,633

85,295

Total other segment items

$

124,890

$

76,275

$

232,777

$

221,698

(b)All other includes cost of goods sold, royalty, travel and entertainment, distribution costs, bad debt expense, finance costs, contract labor costs, stock compensation expense, change in the fair value of contingent consideration, and other expense.